Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 369 Issue 6481, 16 June 1994

Opinion

  • Advertisement

  • Next week's meeting of the CERN Council will not, after all, provide the full-throated endorsement of the Large Hadron Collider for which physicists had been hoping. But cautious governments should restrain misanthropy.

    Opinion
  • The US Congress is in bitter dispute about health reform and the proposed employer mandates.

    Opinion
  • Britain's internal market in health care has made problems for research.

    Opinion
Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

News & Views

Top of page ⤴

Scientific Correspondence

Top of page ⤴

Book Review

Top of page ⤴

Article

  • Physiological platelet synthesis is thought to require the humoral activities of meg-CSF and thrombopoietin, which respectively promote proliferation and maturation of megakaryocytic cells. A meg-CSF/thrombopoietin-like protein that is present in plasma of irradiated pigs has been purified and cloned. This protein binds to and activates the c-mpl protein, a member of the cytokine receptor superfamily. The isolated Mpl ligand shares homology with erythropoietin and stimulates both megakaryocytopoiesis and thrombopoiesis.

    • Frederic J. de Sauvage
    • Philip E. Hass
    • Dan L. Eaton
    Article
Top of page ⤴

Letter

Top of page ⤴

Correction

Top of page ⤴

Product Review

  • New tools for the chromatographer include an analytical workstation for the characterization and analysis of biomolecules by immunoassay and chromatography, and an assortment of columns, pumps, detectors and accessories.

    Product Review
Top of page ⤴

Science and the Law

  • In considering the grounds on which to award patents for applications of germline gene therapy, the European Patent Office may have to decide on the basis of "morality". This should not be its job.

    • Richard Price
    • Simon Cohen
    Science and the Law
Top of page ⤴

Guide to Authors

Top of page ⤴
Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links